Suppr超能文献

中国成年双相障碍患者丙戊酸的群体药代动力学。

Population pharmacokinetics of valproic acid in adult Chinese patients with bipolar disorder.

机构信息

The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.

Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.

出版信息

Eur J Clin Pharmacol. 2022 Mar;78(3):405-418. doi: 10.1007/s00228-021-03246-2. Epub 2021 Dec 2.

Abstract

PURPOSE

To develop and validate a population pharmacokinetic (PPK) model of valproic acid (VPA) in adult Chinese patients with bipolar disorder, and provide guidance for individualized therapy in this population.

METHODS

A total of 1104 serum concentrations from 272 patients were collected in this study. The data analysis was performed using a nonlinear mixed-effects modeling approach. Covariates included demographic parameters, biological characteristics, and concomitant medications. Bootstrap validation (1000 runs), normalized prediction distribution error (NPDE), and external validation of 50 patients were employed to evaluate the final model.

RESULTS

A one-compartment model with first-order absorption and elimination was developed for VPA extended-release tablets. VPA clearance was significantly influenced by three variables: sex (12% higher in male patients), daily dose (increasing with the 0.13 exponent), and body weight (increasing with the 0.56 exponent). Typical values for the absorption rate constant (K), apparent clearance (CL/F), and apparent distribution volume (V/F) for a female patient weighing 70 kg administered VPA 1000 mg/day were 0.18 h, 0.46 L/h, and 12.84 L, respectively. The results of model evaluation indicated a good stable and precise performance of the final model.

CONCLUSIONS

A qualified PPK model of VPA was developed in Chinese patients with bipolar disorder. This model could be used as a suitable tool for the personalization of VPA dosing for bipolar patients.

摘要

目的

建立并验证一种用于治疗成人双相情感障碍患者的丙戊酸群体药代动力学(PPK)模型,为该人群的个体化治疗提供指导。

方法

本研究共纳入 272 例患者的 1104 份血清浓度数据。数据分析采用非线性混合效应模型法。协变量包括人口统计学参数、生物学特征和伴随药物。采用 Bootstrap 验证(1000 次重复)、归一化预测分布误差(NPDE)和 50 例患者的外部验证来评估最终模型。

结果

建立了丙戊酸钠缓释片的一室模型,具有一级吸收和消除。丙戊酸清除率受三个变量显著影响:性别(男性患者清除率高 12%)、日剂量(与 0.13 次幂呈正相关)和体重(与 0.56 次幂呈正相关)。对于体重 70kg、每日给予丙戊酸钠 1000mg 的女性患者,吸收速率常数(K)、表观清除率(CL/F)和表观分布容积(V/F)的典型值分别为 0.18h、0.46L/h 和 12.84L。模型评价结果表明,最终模型具有良好的稳定性和精确性。

结论

建立了一种适用于中国双相情感障碍患者的丙戊酸 PPK 模型。该模型可作为双相患者丙戊酸剂量个体化的合适工具。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验